All Stories

  1. Effectiveness and Safety of Statins in Type 2 Diabetes According to Baseline Cardiovascular Risk
  2. Risk of hyperglycemia and new-onset diabetes among new users of medications for overactive bladder: population-based cohort study
  3. Unpacking Oral Challenge Protocols: A Descriptive Epidemiologic Study of Reactions, Predictors, and Practices for Delabeling Low-Risk Penicillin Allergies Leveraging Data from a Systematic Review and Meta-Analysis
  4. Risk of Hospital Presentation with Hypoglycemia Among Users of Beta-blockers with Diabetes: Population-Based Nested Case–Control Study
  5. A systematic review and meta‐analysis of interventions to delabel low‐risk penicillin allergies with consideration for sex and gender
  6. Examining hypoglycemia risk with systemic fluoroquinolone use: A systematic review and meta-analysis
  7. Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
  8. Insulin, hypoglycaemia and dementia: A causal mediation analysis showcasing challenges and potential opportunities
  9. Post‐initiation predictors of discontinuation of the sodium‐glucose cotransporter‐2 inhibitors: A comparative cohort study from the United Kingdom
  10. Insulin Use in Type 2 Diabetes and the Risk of Dementia: A Comparative Population-Based Cohort Study
  11. Author’s Reply to Kuss and Rathmann’s Comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data”
  12. Trends in estimated total retail dispensed prescriptions of purported COVID-19 treatments and preventions in Canada
  13. Prescribing Trends of the Sodium–Glucose Cotransporter-2 Inhibitors Among Different Physician Specialties in Canada (2015–2021)
  14. Risk of all-cause mortality or hospitalization for pneumonia associated with inhaled β2-agonists in patients with asthma, COPD or asthma-COPD overlap
  15. Associations of Mid- and Late-Life Severe Hypoglycemic Episodes With Incident Dementia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study
  16. Hypoglycaemia and the risk of dementia: a population-based cohort study using exposure density sampling
  17. Authors’ Reply to Noguchi’s comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.”
  18. Peak performance: Putting type 1 diabetes management recommendations for athletes to the test
  19. Five comparative cohorts to assess the risk of genital tract infections associated with sodium‐glucose cotransporter‐2 inhibitors initiation in type 2 diabetes mellitus
  20. Association between Inhaled β2-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study
  21. Variation in bleeding risk estimates among online calculators
  22. Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs
  23. Drug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data
  24. Active‐comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors
  25. Sodium-glucose cotransporter-2 inhibitors and urinary tract infections: A propensity score matched population-based cohort study.
  26. Trends and Determinants of Self-Reported Aspirin Use among Patients with Diabetes Stratified by the Presence and Risk of Cardiovascular Diseases - Repeated Pan-Canadian Cross-Sectional Study
  27. Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study
  28. Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
  29. Variation and appropriateness of antipsychotic use in long-term care facilities across Newfoundland and Labrador
  30. Sodium/Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events
  31. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews
  32. Gender Differences in Inhaled Pharmacotherapy Utilization in Patients with Obstructive Airway Diseases (OADs): A Population-Based Study
  33. Perceptions of Patients Regarding Mobile Health Interventions for the Management of Chronic Obstructive Pulmonary Disease: Mixed Methods Study
  34. The association of sodium‐glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews
  35. Too young for Cannabis? Choice of minimum legal age for legalized non-medical Cannabis in Canada
  36. Thiazide Diuretic–Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials
  37. Capturing Adult Patient Preferences Toward Benefits and Risks of Second-Line Antihyperglycemic Medications Used in Type 2 Diabetes: A Discrete Choice Experiment
  38. Features of a mobile health intervention to manage chronic obstructive pulmonary disease: a qualitative study
  39. Perceptions of Patients Regarding Mobile Health Interventions for the Management of Chronic Obstructive Pulmonary Disease: Mixed Methods Study (Preprint)
  40. Comparative Safety and Effectiveness of Inhaled Bronchodilators and Corticosteroids for treating Asthma-COPD Overlap: A Systematic Review and Meta-Analysis
  41. Perceptions of Health Care Providers Regarding a Mobile Health Intervention to Manage Chronic Obstructive Pulmonary Disease: Qualitative Study
  42. Perceptions of Health Care Providers Regarding a Mobile Health Intervention to Manage Chronic Obstructive Pulmonary Disease: Qualitative Study (Preprint)
  43. Validated methods to identify patients with asthma–COPD overlap in healthcare databases: a systematic review protocol
  44. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
  45. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes
  46. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink
  47. Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials
  48. Capsule Commentary on Franklin et al., Time to Filling of New Prescriptions for Chronic Disease Medications Among a Cohort of Elderly Patients in the USA
  49. A systematic assessment of the availability and clinical drug information coverage of machine-readable clinical drug data sources for building knowledge translation products
  50. Measuring the impact of pharmacoepidemiologic research using altmetrics: A case study of a CNODES drug-safety article
  51. Diabetes and the occurrence of infection in primary care: a matched cohort study
  52. The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study
  53. The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin
  54. The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Systematic Review and Meta-Analysis
  55. The association between diabetes mellitus and incident infections: a systematic review and meta-analysis of observational studies
  56. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study
  57. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis
  58. Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial
  59. The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review and Meta-Analysis
  60. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users
  61. Factors associated with early insulin initiation in Type 2 diabetes: a Canadian cross-sectional study
  62. Medical Practice Variations in Diabetes Mellitus
  63. Incretin-based medications for type 2 diabetes: an overview of reviews
  64. Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review
  65. Limited Impact of Drug Exposure Misclassification From Non-Benefit Thiazolidinedione Drug Use on Mortality and Hospitalizations From Saskatchewan, Canada: A Cohort Study
  66. Medication transitions and polypharmacy in older adults following acute care
  67. Changes in Thiazolidinedione Use and Outcomes Following Removal of a Prior-authorization Policy
  68. Medical Practice Variations in Diabetes Mellitus
  69. Use Patterns of Antidiabetic Regimens by Patients with Type 2 Diabetes
  70. Clinically Relevant Efficacy of Insulin Therapy in Patients with Type 2 Diabetes
  71. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study
  72. Evaluating the introduction of a computerized prior-authorization system on the completeness of drug exposure data
  73. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study
  74. Stress Hyperglycemia and Newly Diagnosed Diabetes in 2124 Patients Hospitalized with Pneumonia
  75. Restrictive Drug Coverage Policies can Induce Substantial Drug Exposure Misclassification in Pharmacoepidemiologic Studies
  76. Guideline adherence and macrolides reduced mortality in outpatients with pneumonia
  77. Quantifying the Impact of Drug Exposure Misclassification due to Restrictive Drug Coverage in Administrative Databases: A Simulation Cohort Study
  78. Patient-Level Evaluation of Community-Based, Multifactorial Intervention to Prevent Diabetic Nephropathy in Northern Alberta, Canada
  79. Analysis of drug coverage before and after the implementation of Canada's Common Drug Review
  80. Effect of Aspirin Dose on Mortality and Cardiovascular Events in People with Diabetes: A Meta-Analysis
  81. Patterns of Care and Outcomes Differ for Urban Versus Rural Patients With Newly Diagnosed Heart Failure, Even in a Universal Healthcare System
  82. Oxygen Saturations Less than 92% Are Associated with Major Adverse Events in Outpatients with Pneumonia: A Population-Based Cohort Study
  83. Review: Statin use increases risk for diabetes
  84. Admission Hypoglycemia and Increased Mortality in Patients Hospitalized with Pneumonia
  85. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study
  86. Dysglycaemia and 90 day and 1 year risks of death or readmission in patients hospitalised for community-acquired pneumonia
  87. The Darkening Cloud of Diabetes: Do trends in cardiovascular risk management provide a silver lining?